N4bp2l1 Inhibitors
Chemical inhibitors of N4bp2l1 employ various mechanisms to interfere with the normal function of this protein. Staurosporine operates by obstructing protein kinases that are instrumental in the phosphorylation of substrates that interact with N4bp2l1, leading to its inhibition. This is similarly the case with Wortmannin and LY294002, both of which target the phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, these compounds can disrupt phosphorylation signaling pathways essential for the activity of N4bp2l1. PD98059 and U0126 impede the mitogen-activated protein kinase kinase (MEK), which sits upstream of various signaling cascades. The inhibition of MEK leads to reduced phosphorylation of downstream proteins that may include or regulate N4bp2l1, thereby decreasing N4bp2l1 activity.
Further, SP600125 and SB203580 specifically inhibit the c-Jun N-terminal kinase (JNK) and p38 MAP kinase, respectively. These kinases are part of signaling pathways that can contribute to the functional state of N4bp2l1, and their inhibition can result in reduced N4bp2l1 activity. On the other hand, PP2 and Dasatinib are known to target tyrosine kinases. PP2 inhibits Src family tyrosine kinases, while Dasatinib is a broader spectrum tyrosine kinase inhibitor, both leading to the suppression of pathways that involve tyrosine phosphorylation of proteins that engage N4bp2l1. Moreover, Rapamycin acts on the mTOR pathway, which is linked to protein synthesis and may indirectly affect proteins that regulate N4bp2l1. Lastly, Bortezomib and MG132, both proteasome inhibitors, can lead to an accumulation of misfolded proteins, potentially disrupting the cellular processes and pathways that include N4bp2l1, hence inhibiting its function. These chemical inhibitors collectively elucidate the complex web of regulatory interactions and signaling pathways that govern the activity of N4bp2l1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
As an inhibitor of protein kinases, Staurosporine can inhibit N4bp2l1 by targeting kinases that are responsible for phosphorylating substrates that interact with or modify the activity of N4bp2l1, leading to its functional inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which could play a role in phosphorylation signaling pathways that include N4bp2l1, leading to decreased activity of N4bp2l1 when PI3K is inhibited. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that can inhibit signaling pathways involving N4bp2l1 by preventing PI3K-related phosphorylation that is necessary for N4bp2l1 functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of various signaling pathways. By inhibiting MEK, PD98059 can decrease the functional activity of N4bp2l1 by reducing the phosphorylation of downstream targets that may include or regulate N4bp2l1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As an inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can reduce the activity of N4bp2l1 by inhibiting JNK-mediated signaling pathways that might contribute to the functional state of N4bp2l1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which can inhibit the functional activity of N4bp2l1 by blocking the p38 MAPK signaling pathway that could be involved in the regulation of N4bp2l1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126, an inhibitor of MEK1/2, can inhibit the functional activity of N4bp2l1 by impairing the MEK/ERK pathway that may be responsible for modulating N4bp2l1 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family tyrosine kinase inhibitor, which can inhibit pathways involving tyrosine phosphorylation that engage N4bp2l1, leading to the functional inhibition of N4bp2l1. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a broad spectrum tyrosine kinase inhibitor, can functionally inhibit N4bp2l1 by inhibiting kinases that regulate its activity through phosphorylation-dependent mechanisms. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which is involved in protein synthesis and may indirectly affect proteins that regulate the function of N4bp2l1, leading to its inhibition. | ||||||